The approval of a disease-modifying treatment for Alzheimer's disease: impact and consequences for the nuclear medicine community

EANM Neuroimaging Comm; Valentina Garibotto; Nathalie L. Albert; Henryk Barthel; Bart van Berckel; Ronald Boellaard; Matthias Brendel; Diego Cecchin; Ozgul Ekmekcioglu; Elsmarieke van de Giessen; Eric Guedj; Adriaan A. Lammerstma; Franck Semah; Tatjana Traub-Weidinger; Donatienne Van Weehaeghe; Silvia Morbelli

doi:10.1007/s00259-021-05485-y

The approval of a disease-modifying treatment for Alzheimer's disease: impact and consequences for the nuclear medicine community

EANM Neuroimaging Comm, Valentina Garibotto^*, Nathalie L. Albert, Henryk Barthel, Bart van Berckel, Ronald Boellaard, Matthias Brendel, Diego Cecchin, Ozgul Ekmekcioglu, Elsmarieke van de Giessen, Eric Guedj, Adriaan A. Lammerstma, Franck Semah, Tatjana Traub-Weidinger, Donatienne Van Weehaeghe, Silvia Morbelli

^*Corresponding author for this work

Faculty of Medical Sciences/UMCG

Research output: Contribution to journal › Editorial › Academic › peer-review

7 Citations (Scopus)

10 Downloads (Pure)

Original language	English
Pages (from-to)	3033-3036
Number of pages	4
Journal	European Journal of Nuclear Medicine and Molecular Imaging
Volume	48
Issue number	10
Early online date	17-Jul-2021
DOIs	https://doi.org/10.1007/s00259-021-05485-y
Publication status	Published - Sept-2021

Keywords

AMYLOID-PET
BIOMARKERS
DEMENTIA
TRIALS

Access to Document

10.1007/s00259-021-05485-y

The approval of a disease-modifying treatment for Alzheimer’s disease- impact and consequences for the nuclear medicine communityFinal publisher's version, 405 KBLicence: Taverne

Handle.net

Persistent link

Cite this

EANM Neuroimaging Comm, Garibotto, V., Albert, N. L., Barthel, H., van Berckel, B., Boellaard, R., Brendel, M., Cecchin, D., Ekmekcioglu, O., van de Giessen, E., Guedj, E., Lammerstma, A. A., Semah, F., Traub-Weidinger, T., Van Weehaeghe, D., & Morbelli, S. (2021). The approval of a disease-modifying treatment for Alzheimer's disease: impact and consequences for the nuclear medicine community. European Journal of Nuclear Medicine and Molecular Imaging, 48(10), 3033-3036. https://doi.org/10.1007/s00259-021-05485-y

@article{c86db28bea9c4ccc948398794d7d8f1c,

title = "The approval of a disease-modifying treatment for Alzheimer's disease: impact and consequences for the nuclear medicine community",

keywords = "AMYLOID-PET, BIOMARKERS, DEMENTIA, TRIALS",

author = "{EANM Neuroimaging Comm} and Valentina Garibotto and Albert, {Nathalie L.} and Henryk Barthel and {van Berckel}, Bart and Ronald Boellaard and Matthias Brendel and Diego Cecchin and Ozgul Ekmekcioglu and {van de Giessen}, Elsmarieke and Eric Guedj and Lammerstma, {Adriaan A.} and Franck Semah and Tatjana Traub-Weidinger and {Van Weehaeghe}, Donatienne and Silvia Morbelli",

year = "2021",

month = sep,

doi = "10.1007/s00259-021-05485-y",

language = "English",

volume = "48",

pages = "3033--3036",

journal = "European Journal of Nuclear Medicine and Molecular Imaging",

issn = "1619-7070",

publisher = "Springer",

number = "10",

}

EANM Neuroimaging Comm, Garibotto, V, Albert, NL, Barthel, H, van Berckel, B, Boellaard, R, Brendel, M, Cecchin, D, Ekmekcioglu, O, van de Giessen, E, Guedj, E, Lammerstma, AA, Semah, F, Traub-Weidinger, T, Van Weehaeghe, D & Morbelli, S 2021, 'The approval of a disease-modifying treatment for Alzheimer's disease: impact and consequences for the nuclear medicine community', European Journal of Nuclear Medicine and Molecular Imaging, vol. 48, no. 10, pp. 3033-3036. https://doi.org/10.1007/s00259-021-05485-y

The approval of a disease-modifying treatment for Alzheimer's disease: impact and consequences for the nuclear medicine community. / EANM Neuroimaging Comm; Garibotto, Valentina; Albert, Nathalie L. et al.
In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 48, No. 10, 09.2021, p. 3033-3036.

Research output: Contribution to journal › Editorial › Academic › peer-review

TY - JOUR

T1 - The approval of a disease-modifying treatment for Alzheimer's disease

T2 - impact and consequences for the nuclear medicine community

AU - EANM Neuroimaging Comm

AU - Garibotto, Valentina

AU - Albert, Nathalie L.

AU - Barthel, Henryk

AU - van Berckel, Bart

AU - Boellaard, Ronald

AU - Brendel, Matthias

AU - Cecchin, Diego

AU - Ekmekcioglu, Ozgul

AU - van de Giessen, Elsmarieke

AU - Guedj, Eric

AU - Lammerstma, Adriaan A.

AU - Semah, Franck

AU - Traub-Weidinger, Tatjana

AU - Van Weehaeghe, Donatienne

AU - Morbelli, Silvia

PY - 2021/9

Y1 - 2021/9

KW - AMYLOID-PET

KW - BIOMARKERS

KW - DEMENTIA

KW - TRIALS

U2 - 10.1007/s00259-021-05485-y

DO - 10.1007/s00259-021-05485-y

M3 - Editorial

SN - 1619-7070

VL - 48

SP - 3033

EP - 3036

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

IS - 10

ER -